NCT01223339 - Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Ertugliflozin

Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state

DRUG

Placebo

Placebo tablets to Ertugliflozin administered in the fasted state

DRUG

Ertugliflozin

Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days

DRUG

Placebo

Placebo tablets administered once daily in the fed state for 7 days